Fig. 6.
CD95L-DCs induce skin allograft rejection.
Ten bm13 mice were inoculated subcutaneously into the footpad with either 3 × 105 control (▴), CD95L (▪) DCs or were untreated (●). After 5 days, C57BL/6 skin allografts were performed and graft survival was monitored daily (*P < .001 for CD95L-DC–treated mice compared with control-DC injected or untreated mice).
